Perawatan Sklerosis lateral amiotrofik di Israel — dapatkan 3 kecocokan klinik pribadi

Israel saat ini menjadi tuan rumah uji klinis lanjutan untuk ALS, termasuk studi Fase 3 penting dari PrimeC dan Fase 3b untuk terapi sel punca NurOwn. Uji coba ini menargetkan neuroinflamasi dan regenerasi saraf di pusat-pusat seperti Sourasky Medical Center dan Hadassah Medical Center. Para peneliti juga mengevaluasi sel punca autologus NG01 dan terapi gen berbasis RNA untuk memperlambat perkembangan penyakit.

• Fase 3 PrimeC: Obat kombinasi oral yang menargetkan neuroinflamasi, memulai uji coba penting pada tahun 2025.
• Terapi sel NurOwn: Perawatan sel punca autologus dengan manufaktur lokal di Sourasky Medical Center.
• Sel punca NG01: Studi jangka panjang di Hadassah menunjukkan 45% peserta melebihi kelangsungan hidup 10 tahun.
• Terapi AstroRx: Pendekatan berbasis sel menggunakan astrosit sehat untuk mendukung neuron yang rusak.

Wawasan Pakar Bookimed: Data menunjukkan bahwa Israel adalah lokasi utama untuk uji coba spesifik mutasi, terutama untuk SOD1 dan varian genetik langka. Klinik khusus seperti yang dipimpin oleh Prof. Dr. Viviean Drory di Sourasky Medical Center memadukan protokol eksperimental ini dengan keahlian elektrofisiologi selama lebih dari 30 tahun. Integrasi ini sering kali memungkinkan pasien untuk mengakses obat-obatan inovatif 6–12 bulan sebelum mencapai pasar internasional yang lebih luas.

Konsensus Pasien: Pasien mencatat bahwa tes genetik dini sangat penting karena banyak uji coba Israel sekarang memerlukan kecocokan biomarker tertentu. Mereka juga menekankan bahwa proses pendaftaran dapat memakan waktu lebih dari 6 bulan, sehingga pendaftaran awal dengan basis data rumah sakit sangat penting.

Perawatan standar ALS di Israel menggunakan Riluzole dan Edaravone untuk memperlambat perkembangan penyakit. Pusat spesialis seperti Sourasky Medical Center (Ichilov) juga menawarkan Tofersen bagi pasien dengan mutasi SOD1. Obat-obatan ini sering dikombinasikan dengan terapi simtomatik multidisiplin untuk meningkatkan kualitas hidup dan fungsi pernapasan.

• Riluzole: Antagonis glutamat lini pertama yang tersedia dalam bentuk tablet atau cair untuk memperpanjang kelangsungan hidup.
• Edaravone: Antioksidan yang diberikan melalui siklus infus intravena untuk memperlambat penurunan fungsi pada pasien.
• Tofersen: Terapi target untuk mutasi genetik SOD1 yang diberikan melalui suntikan tulang belakang khusus.
• Obat simtomatik: Relaksan otot seperti Baclofen dan Tizanidine untuk mengatasi kejang yang menyakitkan dan spastisitas.

Wawasan Pakar Bookimed: Data menunjukkan bahwa memilih pusat dengan volume tinggi seperti Sourasky Medical Center, yang menangani lebih dari 400.000 pasien setiap tahun, memberikan akses yang lebih baik ke protokol canggih. Prof. Dr. Viviean Drory di fasilitas ini memiliki pengalaman lebih dari 35 tahun dalam penilaian elektrofisiologis. Keahlian tersebut sangat penting untuk diagnosis dini yang diperlukan guna memulai terapi Edaravone secara efektif.

Konsensus Pasien: Pasien mencatat bahwa meskipun Riluzole adalah standar, bulan pertama mungkin melibatkan efek samping seperti mual. Banyak yang menekankan pentingnya meminta kombinasi Riluzole dan Edaravone sejak dini untuk memaksimalkan stabilitas.

Israel memiliki pusat ALS multidisiplin utama di Sourasky Medical Center, Hadassah Medical Center, dan Sheba Medical Center. Fasilitas ini menggunakan model satu atap. Pasien mendapatkan akses ke ahli saraf, terapis pernapasan, dan fisioterapi dalam satu kunjungan. Spesialis terkemuka seperti Prof. Dr. Vivian Drory memberikan perawatan ahli.

• Sourasky Medical Center: Memiliki Departemen Neuromuskular khusus yang dipimpin oleh Prof. Dr. Vivian Drory.
• Hadassah Medical Center: Mengoperasikan klinik ALS khusus yang dikenal karena akses ke uji klinis tingkat lanjut.
• Sheba Medical Center: Menyediakan perawatan integratif termasuk rehabilitasi neurologis dan pemantauan rumah khusus.
• Rambam Medical Center: Menawarkan unit Rawat Inap Siang Neurologi untuk layanan medis neuromuskular yang terkonsolidasi.

Wawasan Pakar Bookimed: Pusat ALS Israel menonjol karena mereka mengintegrasikan penelitian langsung ke dalam perawatan klinis. Misalnya, Hadassah Medical Center bertindak sebagai pemimpin global dalam penelitian genetik dan uji coba sel punca. Meskipun Sourasky (Ichilov) tetap menjadi pilihan utama bagi pasien internasional karena peringkatnya yang tinggi di Newsweek, para ahlinya seperti Prof. Dr. Vivian Drory membawa lebih dari 35 tahun pengalaman khusus. Kombinasi praktik klinis bervolume tinggi dan penemuan ilmiah aktif ini sering kali memungkinkan pasien untuk mengakses protokol eksperimental lebih awal daripada di banyak wilayah lain.

Konsensus Pasien: Pasien mencatat bahwa pusat-pusat ini memberikan akses yang sangat cepat ke tim khusus termasuk ahli paru dan ahli gizi. Banyak yang menghargai terapi wicara terintegrasi dan dukungan ventilator di Ichilov karena secara signifikan meningkatkan kualitas hidup sehari-hari.

Pasien internasional dapat mendaftar dalam uji klinis ALS di Israel dengan persetujuan Kementerian Kesehatan dan kuota studi tertentu. Partisipasi sering kali memerlukan pendanaan mandiri untuk perawatan eksperimental. Pusat-pusat terkemuka seperti Hadassah Medical Center dan Tel Aviv Sourasky Medical Center (Ichilov) sering menjadi tuan rumah uji coba global untuk terapi sel punca dan gen.

• Pengawasan regulasi: Kementerian Kesehatan Israel mengelola pendaftaran warga negara asing melalui persetujuan uji coba khusus.
• Potensi biaya: Terapi eksperimental untuk peserta internasional mungkin memerlukan pendanaan pribadi yang signifikan atau subsidi.
• Institusi terkemuka: Hadassah Medical Center melakukan studi besar tentang terapi NG01 dan AstroRx.
• Keahlian khusus: Prof. Viviean Drory di Ichilov berspesialisasi dalam penelitian genetik ALS dan terapi obat.

Wawasan Pakar Bookimed: Data dari fasilitas utama Israel menunjukkan konsentrasi tinggi penelitian ALS di Tel Aviv dan Yerusalem. Meskipun Ichilov melayani lebih dari 400.000 pasien setiap tahun, departemen neuromuskular khususnya sering memprioritaskan pasien berdasarkan tingkat perkembangan penyakit. Pasien harus mencari uji coba dengan label akses yang diperluas. Ini biasanya menawarkan lebih banyak fleksibilitas bagi mereka yang bepergian dari luar Uni Eropa atau Amerika Utara.

Konsensus Pasien: Pasien menekankan perlunya menganggarkan biaya perjalanan dan penginapan yang signifikan selama uji coba jangka panjang. Banyak yang merekomendasikan untuk memprioritaskan pusat yang menyediakan formulir persetujuan dalam bahasa Inggris untuk menghindari hambatan terjemahan tambahan selama proses penyaringan.

Israel is a global hub for Amyotrophic Lateral Sclerosis (ALS) research. Leading hubs like Hadassah Medical Center and Sourasky Medical Center offer advanced cell therapies. Key treatments include autologous NG01 infusions and the NurOwn platform. These therapies aim to slow disease progression and extend survival.

• NG01 therapy: Uses patients' own bone marrow cells. This treatment reported a 7.2-year median survival.
• AstroRx technology: Off-the-shelf astrocytes support motor neurons. Single doses have paused disease progression.
• NurOwn platform: Re-engineered stem cells secrete neurotrophic factors. These factors protect nerves and reduce inflammation.
• Clinical specialists: Experts like Prof. Viviean Drory at Sourasky specialise in ALS palliative care.

Bookimed Expert Insight: Israeli oncology and neurology centres, such as JCI-accredited Sourasky Medical Center, serve over 400,000 patients annually. While clinical trials often have strict entry criteria, the density of university-affiliated research centres in Tel Aviv and Jerusalem creates one of the highest volumes of experimental ALS access points globally. Patients should confirm if a doctor specialises in clinical neurophysiology to ensure the most accurate disease monitoring.

Patient Consensus: Patients note that Israel is a significant biomedical hub, although stem cell treatments are considered experimental. They emphasise checking eligibility early and requesting specific cell data in writing before travel.

Israel offers targeted gene therapies for specific genetic forms of Amyotrophic Lateral Sclerosis (ALS), including the first commercially approved RNA-targeted treatments. Leading university centres in Tel Aviv and Jerusalem provide advanced genetic testing to identify mutations like SOD1. These facilities also run clinical trials for next-generation therapies.

• Tofersen therapy: Targeted treatment available for the SOD1 mutation to suppress toxic protein production.
• Genetic screening: Specialists use diagnostic testing to confirm pathogenic variants before starting targeted interventions.
• RNA-based trials: Research focuses on halting nerve cell degeneration through microRNA-126 and similar pathways.
• Advanced neurology: Experts like Professor Viviean Drory specialise in neurophysiology and clinical management of ALS.

Bookimed Expert Insight: Israeli medical centres often integrate multi-stage biological treatments. For example, Sourasky Medical Center offers stem cell therapy packages starting from A$8,750. These packages often include blood work and follow-up care. This allows patients to combine supportive biological therapies with targeted genetic diagnostic protocols at a single high-volume facility.

Patient Consensus: Patients note that genetic confirmation is essential before travelling to Israel. They emphasize that while some treatments are approved, many others are only available via clinical trials. Families value the detailed advice from competent doctors in Tel Aviv who handle complex neurological cases.

Standard disease-modifying medications for Amyotrophic Lateral Sclerosis in Israel include Riluzole and Edaravone. Specialists prescribe these through the national health basket (Sal HaBriut). Israeli neurologists focus on early administration. JCI-accredited centres like Sourasky Medical Center provide these within comprehensive neuro-palliative care frameworks.

• Riluzole protocol: Core standard medication usually offered to patients immediately following diagnosis.
• Edaravone availability: Prescribed on a case-by-case basis depending on specific clinical criteria.
• Clinical neurophysiology: Experts like Prof. Viviean Drory use electromyography to monitor treatment response.
• Integrated support: Clinics bundle medications with symptom management for spasticity and saliva control.

Bookimed Expert Insight: Israeli neurology units treat an immense volume of patients, with Hadassah Medical Center serving approximately 1,000,000 people annually. This high-volume environment allows specialists to identify which patients respond best to Edaravone versus Riluzole. Patients should confirm if their prescribed medication plan includes on-site electrophysiology monitoring. This ensures the dosage remains effective as the condition evolves.

Patient Consensus: Patients note that Riluzole is the standard starting point in Israel. They emphasize that while disease-modifying drugs are vital, additional prescriptions for cramps and sleep significantly improve daily life.

Israel manages ALS through integrated multidisciplinary hubs where neurologists, pulmonologists, and therapists coordinate care in a single visit. This one-stop shop model ensures immediate access to respiratory support, nutritional management, and speech technology. Leading facilities like Sourasky Medical Center and Hadassah Medical Center prioritise patient autonomy and comfort.

• Integrated clinics: Teams evaluate patients in one day to streamline complex specialist coordination.
• Respiratory support: Specialists initiate non-invasive ventilation early to manage nighttime fatigue and breathing.
• Nutritional care: Gastroenterologists offer feeding tubes early to maintain weight and prevent choking.
• Symptom medication: Doctors prescribe targeted drugs for muscle cramps, spasticity, and excessive saliva.

Bookimed Expert Insight: Israeli neuromuscular centres excel in high-volume care, with Sourasky Medical Center alone serving over 400,000 patients annually. Our data shows that top specialists like Dr Viviean Drory combine clinical neurophysiology with advanced electromyography. This technical depth allows for more precise symptom tracking than general clinics typical in other regions.

Patient Consensus: Patients in Israel highlight the importance of setting up eye-gaze communication devices early. They note that practical planning for home equipment and pressure care is vital before returning home to Australia.

Israel's leading ALS neurologists include Prof. Vivian Drory at Sourasky Medical Center and Prof. Dimitrios Karussis at Hadassah Medical Center. These specialists lead neuromuscular units, focusing on advanced electromyography and stem cell trials. Major Israeli centres provide multidisciplinary care for managing neurodegenerative symptoms.

• Prof. Vivian Drory: Directs the Neuromuscular Diseases Unit at Sourasky, specialising in clinical neurophysiology.
• Prof. Dimitrios Karussis: Leads neuroimmunology at Hadassah, known for clinical trials using adult stem cells.
• Dr. Amir Dori: Heads the Neuromuscular Disorders Department at Sheba Medical Center, researching protein accumulation.
• Dr. Eduard Linecki: Serves as a senior neurologist at Hadassah with over 20 years of experience.

Bookimed Expert Insight: Israeli neurology units like Ichilov and Hadassah manage massive patient volumes, often seeing 1,000,000 cases annually. This scale allows specialists to focus strictly on motor neuron diseases rather than general neurology. Professor Vivian Drory, for instance, maintains specific memberships in international research alliances for ALS, ensuring patients access global-standard palliative and drug therapies.

Patient Consensus: Patients find that choosing hospitals with integrated physiotherapy and respiratory support prevents delays. They appreciate the detailed advice from competent doctors in Tel Aviv and note that English-speaking staff simplify complex medical discussions in Israel.

Diagnostic evaluation in Israel for international ALS patients involves a multi-stage review to confirm the diagnosis and assess current function. Clinical specialists use electrophysiology and electromyography (EMG) to measure muscle and nerve electrical activity. Multi-disciplinary teams at JCI-accredited centres then design personalised drug or stem cell therapy plans.

• Record review: Specialists evaluate home-country MRI, EMG, and blood tests before patients travel.
• Neurological assessment: Doctors perform repeat examinations to track symptoms and disease progression carefully.
• Electrophysiology testing: Clinics use advanced clinical neurophysiology to confirm nerve damage patterns accurately.
• Treatment synthesis: Teams include neurologists and rehabilitation specialists to map out therapeutic roadmaps.

Bookimed Expert Insight: Israeli neurology units maintain high precision by requiring fresh EMG tests using their on-site equipment. Experts like Dr Viviean Drory at Sourasky Medical Center specialise specifically in ALS neurophysiology. Our data shows patients benefit most when they provide a documented timeline of symptom progression, as this helps specialists distinguish ALS from similar neuromuscular disorders early.

Patient Consensus: Patients in Israel note that evaluations involve a fresh neurological assessment rather than just accepting prior results. They suggest bringing complete records and planning for a multi-day process as results feed directly into treatment planning.

Israeli researchers recently identified an RNA-based gene therapy that stopped and reserved nerve cell degeneration in ALS models. This discovery targets microRNA-126 to prevent toxic protein buildup. Additionally, long-term data on Hadassah Medical Center stem cell therapy shows a 7.2-year median survival rate.

• Molecular mechanism: Researchers found microRNA-126 transfer failure causes toxic protein clumps in motor neurons.
• Nerve regeneration: Engineered microRNA-126 successfully neutralized toxins and triggered new nerve cell growth.
• Survival data: Hadassah Medical Center reported 45% of patients survived over 10 years post-diagnosis.
• Clinical trials: This programmable neuroprotection method is moving toward human trials for several diseases.

Bookimed Expert Insight: Israeli neurology excels because leading specialists combine clinical practice with high-level research. Dr Viviean Drory at Sourasky Medical Center is a specialist in clinical neurophysiology and electromyography. Her involvement in international research alliances ensures patients access diagnostic techniques that align with the latest scientific breakthroughs before they become global standards.

Patient Consensus: Patients emphasize the need to distinguish between exciting laboratory research news and treatments currently available in clinics. They recommend checking for active clinical trial listings in Israel to verify if a new therapy is accessible for international cases.